Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk

Exclusion Criteria

• •1. Women of childbearing potential or pregnant/nursing women
• •2. CABG surgery in the past 3 years
• •3. Class IV heart failure
• •4. Uncontrolled HTN
• •5. History of tuberculosis or latent TB that is not treated
• •6. Nephrotic syndrome or eGFR\< 30 ml/min/1.73m2
• •7. Active hepatic disease or active/chronic hepatitis B or C
• •8. Any prior malignancy including KS
• •9. Serious illness requiring hospitalization or active infection requiring antibiotics within 90 days
• •10. Requirement for live active vaccination 3 months prior to, during, and 3 months after study
• •11. Concurrent immune modulating therapy
• •12. Diabetes Mellitus
• •13. History of multiple imaging studies associated with radiation exposure
• •14. Neutropenia defined as ANC\<1500/mm
• •15. Triglycerides\>400 mg/dL
• •16. History of hypersensitivity to study drug
• •17. History of EBV-related lymphoproliferative disorders
• •18. Active or untreated latent TB infection